A Million Samples Are Worth More Than the Analyzer

To read a new market signal properly, you run it against the standard curve. This week’s signal: Mayo Clinic and Thermo Fisher announced Precure, a joint venture to analyze one million biospecimens with multi-omics data and artificial intelligence, in search of early-detection biomarkers (official announcement by Mayo Clinic and Thermo Fisher Scientific, September 15, 2026).

You could file it as one more corporate collaboration, the kind that gets signed every week. I believe it marks a deeper change of variable: where the strategic asset of diagnostics actually sits.

The bottleneck moved

For decades, the consolidation conversation in IVD revolved around measurement technology: who built the analyzer, who controlled the reagent flow, who owned the channel. That debate still matters, but the frontier has moved.

In this notebook I have argued that the quality gap between platforms keeps narrowing: there is more analytical capacity available today, at more price points, than at any moment in the history of the industry. When measurement becomes abundant, it stops being the bottleneck. What becomes scarce is what gives measurement its meaning: samples.

And not just any samples. Standardized biospecimens — collected under consistent pre-analytical protocols, accompanied by clinical metadata, with consents in order and, above all, longitudinal: the same patient followed through time. An AI model without such a cohort is not applied intelligence; it is mathematics waiting for a standard.

Measurement technology becomes a commodity; the standardized sample becomes reference material. The standard against which predictive medicine gets calibrated no longer lives in a vial. It lives in a cohort.

What Thermo Fisher actually bought

Through that lens, Precure reads differently. Thermo Fisher is one of the largest laboratory equipment manufacturers in the industry — it was never short of measurement technology. What the joint venture structure buys it is access to something almost nobody else can assemble: the Mayo Clinic biobank, a million samples with hospital-grade standardization and clinical history behind them.

It did not buy analytical capacity. It bought access to the input.

The ownership structure says it out loud: control of Precure stayed with Mayo Clinic — the owner of the biobank — and Thermo Fisher comes in as a minority founding partner, contributing its measurement platforms (Olink Explore HT, Orbitrap). Even the company’s governance landed on the side of the sample, not the instrument.

IVD consolidation has been contested on two classic fronts: equipment and channels. Data joint ventures open a third one, with a different logic. It is not about selling more tests: it is about occupying the ground where the next decade of diagnostics will be trained. Worth naming the asymmetry: a laboratory that sells tests competes on volume and price; a data JV competes on exclusivity of access. They are games with different rules, and the second one has far fewer players.

The reading for those of us operating in LATAM

Three practical implications for laboratories and distributors in the region.

First: the value conversation is no longer just price per test. A sample archive — panel sera, longitudinal controls, residual study banks — is an asset with strategic value. When someone proposes a “study collaboration,” read it for what it is: a data transaction, with the questions of any contract. Who uses the samples, for what, with what exclusivity, in exchange for what.

Second: standardization is the multiplier. A freezer without metadata is inventory. With documented pre-analytics, traceability, and consents, it is a biobank. The difference is not the cold equipment — it is the process.

Third: lock-in does not disappear; it changes currency. If yesterday’s reagent rental locked in the reagent flow, tomorrow’s strategic alliance can lock in the sample flow for research. Better to anticipate it in the negotiation than discover it after signing.

Whoever owns the standardized cohort does not need to compete on the price of the test. They need to decide who gets to run it.

The asset was a person

Every one of those samples came out of someone’s arm: a venipuncture drawn to answer a specific clinical question, from a patient who trusted a laboratory with their blood. Building the future of early detection on that material is legitimate. Forgetting where it came from is not.

“Our actions touch lives” is not a slogan in this industry. It is the literal description of the strategic asset.

When an industry’s asset moves, prices, alliances, and barriers move after it. This essay only aims to see it first, with the curve calibrated — before somebody’s brochure tells the story for us.